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High-resolution crystal structure of human
asparagine synthetase enables analysis of inhibitor
binding and selectivity
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Expression of human asparagine synthetase (ASNS) promotes metastatic progression and
tumor cell invasiveness in colorectal and breast cancer, presumably by altering cellular levels
of L-asparagine. Human ASNS is therefore emerging as a bona ﬁde drug target for cancer
therapy. Here we show that a slow-onset, tight binding inhibitor, which exhibits nanomolar
afﬁnity for human ASNS in vitro, exhibits excellent selectivity at 10 μM concentration in HCT-
116 cell lysates with almost no off-target binding. The high-resolution (1.85 Å) crystal
structure of human ASNS has enabled us to identify a cluster of negatively charged side
chains in the synthetase domain that plays a key role in inhibitor binding. Comparing this
structure with those of evolutionarily related AMP-forming enzymes provides insights into
intermolecular interactions that give rise to the observed binding selectivity. Our ﬁndings
demonstrate the feasibility of developing second generation human ASNS inhibitors as lead
compounds for the discovery of drugs against metastasis.
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Asparagine synthetase (ASNS) catalyzes the ATP-dependent biosynthesis of L-asparagine in cells from L-aspartic acid using L-glutamine as a nitrogen source1.
Several recent ﬁndings provide evidence for connections between
asparagine biosynthesis and human disease, raising the urgency
for in-depth studies of human ASNS. First, asparagine synthetase
deﬁciency (ASD), which is a rare human neurological disorder,
has been linked to residue changes at several locations throughout
the enzyme2. Nothing is known about how these ASD-linked
changes in ASNS impact catalytic activity and stability of the
enzyme, although children with ASD exhibit microcephaly,
epileptic-like seizures, and intellectual disability3. Second, silen-
cing the gene encoding ASNS inhibits cell proliferation in a
murine sarcoma model4 generated by oncogenic forms of Kras5,6.
Third, L-asparagine is important for the growth and maintenance
of acute lymphoblastic leukemia7, and breast8, lung9, and
castration-resistant prostate10 cancers. Finally, altering exogenous
L-asparagine levels affects tumor cell invasiveness, and enforced
expression of human ASNS promotes metastatic progression in
both colorectal11 and breast cancer12 by an undetermined
mechanism. All of these observations strongly suggest that
human ASNS is a bona ﬁde drug target and that potent, small-
molecule ASNS inhibitors will have signiﬁcant clinical utility in
the prevention of metastasis11,12, and perhaps more broadly in
cancer chemotherapy13. In fact, it has been suggested that drugs
that alter the availability of asparagine in the body might be useful
to treat sarcomas with mutant forms of Ras4. Access to highly
speciﬁc, small-molecule ASNS inhibitors that can penetrate cells
will be transformative in establishing the feasibility of targeting
ASNS as a new strategy to treat recalcitrant cancers.
Identifying compounds with nanomolar afﬁnity for human
ASNS, however, has proven to be remarkably difﬁcult. The only
reported screening studies failed to identify small-molecules with
sub-micromolar binding and/or high selectivity for human
ASNS14, probably because of a lack of mechanistic and structural
information about the enzyme. Early work by our group therefore
elucidated the kinetic and catalytic mechanisms of the glutamine-
dependent asparagine synthetase (AS-B)15,16 encoded by the asnB
gene in Escherichia coli17. These studies revealed that both the β-
aspartyl-AMP intermediate and the transition state for its sub-
sequent reaction with ammonia are tightly bound by the enzyme
during catalysis (Fig. 1a)16. Although unreactive analogs of the β-
aspartyl-AMP intermediate are indeed sub-micromolar ASNS
inhibitors18, the functionalized methylsulfoximines 1 and 2
(Fig. 1b), which mimic the key transition state for the attack of
ammonia on activated esters19,20, are slow-onset inhibitors
exhibiting nanomolar afﬁnity for the enzyme in kinetic
assays21,22. Very importantly, ASNS inhibitor 1 (Fig. 1b) nega-
tively impacts the growth of sarcoma cells in a manner similar to
that seen when ASNS expression is decreased using siRNA
knockdown methods4. Moreover, this compound, as a 1:1 mix-
ture of diastereoisomers 1a and 1b (Fig. 1b), is cytotoxic against
asparaginase-resistant MOLT-4 leukemia cells, albeit only at
micromolar concentrations21. Unfortunately, although ASNS
inhibitor 1 might possess anti-cancer properties, its poor bioa-
vailability curtails its usefulness for studies employing animal
models of cancer and metastasis21. Nevertheless, this cytotoxic
ASNS inhibitor can serve as a starting point for drug discovery.
We now report the extent to which ASNS inhibitor 1 participates
in off-target binding in HCT-116 cell lysates together with the
ﬁrst high-resolution X-ray crystal structure of human ASNS, to
our knowledge. Our studies provide an in-depth understanding of
the molecular basis for the speciﬁcity of ASNS inhibitor 1 and
provide a ﬁrm basis for future efforts to generate a second gen-
eration of small-molecule ASNS inhibitors with improved bioa-
vailability and reduced chemical complexity.
Results
Binding speciﬁcity of ASNS inhibitor 1 in HCT-116 lysates. We
undertook KiNativTM chemoproteomic proﬁling experiments23,
employing the chemically reactive probe 3 (Fig. 1)24, in HCT-116
(ATCC CCL-247) cell lysates to evaluate the afﬁnity of ASNS
inhibitor 1 for alternate targets, especially kinases and non-kinase
ATPases. This cell line can metastasize in xenograft models and
has been used in studies of colon cancer proliferation25. In
addition, transcriptome proﬁling indicates that ASNS is expressed
in relatively high amounts in HCT-116 cells (Supplementary
Fig. 1). Additional support for the cancer relevance of this cell line
is provided by recent work showing the importance of asparagine
biosynthesis in colorectal cancer cell proliferation and metas-
tasis11. Based on the clinically relevant plasma concentration of
anticancer drugs26, we incubated the probe molecule 3 with
HCT-116 cell lysates in the presence (10 μM) or absence of ASNS
inhibitor 1. MS/MS fragmentation and sequence analysis of the
tryptic peptides obtained from these reaction mixtures showed
that ASNS inhibitor 1 suppressed the ability of probe 3 to acylate
the side chain of Lys-466 (located within the ATP-binding site of
human ASNS) to an extent of 62% when present in the HCT-116
lysate at 10 μM concentration (Fig. 2). Even though this value is
lower than expected, given that ASNS inhibitor 1 is a slow-onset
inhibitor27 in vitro with a nanomolar Ki*(ref. 21), acylation of the
active site lysine in ASNS was inhibited to the greatest extent for
all ATPases present in the cell lysates. Occupation of the ATP-
binding site by ASNS inhibitor 1 will, of course, vary over time as
a function of the rate at which the initial EI complex isomerizes to
the EI* complex28. The complicated environment of the cell lysate
makes it difﬁcult to quantify the in vitro isomerization rate
constants, but we note that the activity of human ASNS is
decreased approximately three-fold after 15 min in the presence
of 10 μM ASNS inhibitor 1 under our in vitro assay conditions21.
In addition, it is also possible that the ability of ASNS inhibitor 1
to bind to the synthetase site of the enzyme is negatively impacted
by the ATP concentration in the cell lysates21. Importantly, only
moderate suppression of lysine acylation by the reactive probe 3
was observed for a small number of off-target enzymes, including
nicotinate-nucleotide adenylyltransferase29, and argininosucci-
nate synthetase (ASS1)30. There is also a weak interaction of the
ASNS inhibitor 1 with the ATP-binding sites of two ABC
transporters. On the other hand, 10 μM ASNS inhibitor 1 does
not suppress lysine acylation in the ATP-binding sites of phos-
phopantetheine adenylyltransferase31, GMP synthetase32, and
glutamyl-tRNA synthetase33 to any signiﬁcant extent even though
these enzymes also convert ATP to AMP and inorganic pyr-
ophosphate (MgPPi) during catalytic turnover (Fig. 2 and Sup-
plementary Data 1). Although the structurally similar compound
2 (Fig. 1b) binds to the Escherichia coli ammonia-dependent
asparagine synthetase (AS-A)34, which is evolutionarily related to
bacterial amino-acyl tRNA synthetases35, our chemoproteomic
proﬁling studies suggest that ASNS inhibitor 1, when present in
HCT-116 cell lysates at 10 μM concentration, interacts only
weakly with lysyl tRNA synthetase and does not bind to seryl
or asparaginyl tRNA synthetases (Fig. 2 and Supplementary
Data 1). ASNS inhibitor 1 is also bound by UMP-CMP kinase 1
(CMPK1)36 and (to a considerably lesser extent) the kinases
MVK, CMPK2, and AK1. In efforts to rationalize the interaction
of CMPK1 and ASNS inhibitor 1, and assuming that binding
takes place in the ATP-binding site of the kinase, we used manual
docking methods to obtain a model of the 1a/CMPK1 complex
based on the X-ray crystal structure of the homologous enzyme in
Dictyostelium discoideum37 bound to ADP (Supplementary
Fig. 2). Although this model suggests that both epimers 1a and 1b
could possibily interact with the kinase (see Supplementary
Information), any in-depth understanding of their binding
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energetics and intermolecular interactions lies outside the scope
of this paper. Given that (i) the chemoproteomic probe 3 can
target almost the full complement of human kinases38, and (ii)
cells generally express about 40% of the human kinome39, a high
level of selectivity is exhibited by this early-stage AMP-derived
inhibitor at 10 μM concentration. This ﬁnding therefore supports
the idea that a second generation of speciﬁc ASNS inhibitors with
more drug-like chemical structures40 can be developed.
The situation changes somewhat when chemoproteomic assays
of HCT-116 lysates are performed in the presence of 100 μM
ASNS inhibitor 1 (Fig. 2 and Supplementary Data 1). For
example, acylation by the probe 3 is suppressed by over 50% for
29 proteins (Fig. 2), and two- to three-fold increases in inhibition
are observed for CMPK1, nicotinamide mononucleotide adeny-
lyltransferase and the ABC transporters. Increased amounts of
off-target binding to lysyl tRNA synthetase and other protein
kinases in a dose-dependent fashion are also observed. Unex-
pectedly, suppression of Lys-466 acylation in human ASNS only
increases to an extent of 72% when ASNS inhibitor 1 is present at
100 μM concentration (Fig. 2). It is difﬁcult to explain this
relatively small increase in the assay although it may reﬂect
changes in binding kinetics due to the increased extent of
interaction of the inhibitor 1 with other proteins in the lysate. In
addition, because a mixture of epimers 1a and 1b is used in the
assay, the small change in binding to ASNS may reﬂect the fact
that one of these diastereoisomers has much lower afﬁnity for the
enzyme, as discussed below. Finally, the afﬁnity of ASNS inhibitor
1 for both ASS1 and splice isoform 2 of P43686 appears to be
substantially decreased under these conditions (Fig. 2). Given that
the reasons for this observation were not clear, we evaluated the
ability of ASNS inhibitor 1 to bind to human ASS1 using in vitro
kinetic measurements. Recombinant ASS1 was obtained by
expression in Sf9 cells (Expression Systems, LLC), using the
TEQC method for optimizing protein production, and puriﬁed by
metal afﬁnity chromatography (see Supplementary Information).
Incubating the enzyme with substrates in the presence and
absence of 10 μM ASNS inhibitor 1 (see Supplementary Informa-
tion) showed only weak inhibition on the basis of MgPPi
formation (Supplementary Fig. 3). ASS1 activity was further
decreased but not abolished when the ASNS inhibitor 1 was
present at 100 μM concentration. It is therefore possible that weak
off-target interactions with ASS1 can take place in the cell.
Molecular structure of human ASNS. In order to determine the
molecular basis for the binding selectivity of ASNS inhibitor 1
and to provide a ﬁrm basis for future, structure-based efforts to
identify potent and selective ASNS inhibitors with simpliﬁed
molecular scaffolds, we determined the high-resolution crystal
structure of human ASNS by X-ray crystallography at 1.85 Å
resolution (Fig. 3). To date, only the structure of the glutamine-
dependent ASNS encoded by the asnB gene in Escherichia coli has
been reported41. All efforts to obtain crystals of this and other
bacterial ASNS homologs bound to small-molecules other than
AMP have failed42. Moreover, kinetic studies have shown dif-
ferences in the ability of ASNS inhibitor 2 (Fig. 1) to bind human
ASNS and AS-B21,43. For our crystallization experiments, multi-
milligram amounts of highly active, recombinant, C-terminally
His10-tagged, human ASNS were obtained by expression in
Sf9 cells44 using the TEQC method (see Supplementary Infor-
mation)45. The enzyme was initially puriﬁed by metal-afﬁnity
chromatography with subsequent removal of the C-terminal
His10-tag by digestion with the S219P variant of TEV protease46.
The resulting sample of untagged ASNS was then reacted with
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Fig. 1 Catalytic mechanism of human ASNS and structures of compounds 1–4. a Overview of the chemical transformations catalyzed by ASNS showing the
β-aspartyl-AMP intermediate and the transition state for its subsequent reaction with an ammonia molecule, which is released from L-glutamine in a
separate glutaminase site. b Chemical structures for functionalized methylsulfoximines 1 and 2, activity-based probe 3 and 6-diazo-5-oxo-L-norleucine 4
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DON (6-diazo-5-oxo-L-norleucine)47 4 (Fig. 1a) to modify the
reactive thiolate of Cys-1 in the glutaminase active site of ASNS48.
Mass spectrometric analysis of the as-puriﬁed and DON-modiﬁed
protein showed the DON-modiﬁed form of human ASNS to be a
homogeneous protein in which other cysteine residues in the
protein had not been covalently modiﬁed (Supplementary Fig. 4;
Supplementary Note 1). These mass spectrometric measurements
also showed that the N-terminal methionine residue of the
recombinant enzyme had been correctly processed. Conditions
were then identiﬁed that gave a single crystal of the DON-
modiﬁed enzyme (Supplementary Fig. 5), which diffracted to
1.85 Å resolution (Table 1 and Supplementary Fig. 6). The
structure of human ASNS was solved by molecular replacement49
using AS-B41 as a search model. Two molecules of DON-
modiﬁed human ASNS were present in the asymmetric unit as a
head-to-head dimer in which the two monomers were linked by a
disulﬁde bond that likely forms during crystallization (Fig. 3a). As
seen for the bacterial homolog, human ASNS is composed of two
domains (Fig. 3b). Residues in the C-terminal (residues 203–560)
synthetase domain (41.6% identity) are more conserved than
those in the N-terminal (residues 1–202) glutaminase domain
(33.9% identity) based on sequence comparisons of human ASNS
and its homologs in a number of model organisms (Supple-
mentary Fig. 7). The N-terminal domain of human ASNS pos-
sesses the typical sandwich-like α/β/β/α topology present in N-
terminal nucleophile (Ntn) amidotransferases50, such as GMP
synthetase51, and glutamine PRPP amidotransferase52. A cis-
proline (Pro-60) linkage is present in the human enzyme identical
to that in the structure of the bacterial homolog AS-B. Electron
density for the DON-modiﬁed Cys-1 side chain is clearly evident
in each monomer (Fig. 3c). A hydrogen bond network, composed
of the conserved residues Arg-48, Val-52, Asn-74, Gly-75, Glu-76,
and Asp-96, which mediates substrate recognition and thioester
stabilization in the hydrolysis reaction that produces ammonia, is
also clearly deﬁned53. This substrate-binding pocket is located at
the interface of the two domains and is within 5 Å of an abso-
lutely conserved glutamate residue (Glu-414) in the C-terminal
domain (Fig. 3d). After reﬁnement of the protein and ligands, a
single 12 σ peak remained in a pocket at the interface of the N-
and C-terminal domains on both chains. The site is surrounded
by Tyr-78, Arg-416, Arg-245, and Val-417, and the peak was
assigned as a chloride anion (Fig. 3b). The functional importance
of this ﬁnding remains to be established for human ASNS, but
plant asparagine synthetases are known to be activated by
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Fig. 2 Chemoproteomic Proﬁling of ASNS Inhibitor 1 Binding to Cellular ATPases. Percentage inhibition of lysine acylation by the reactive probe 3 in the
presence of ASNS inhibitor 1 at a 10 μM and b 100 μM concentration. The inhibition values are color-coded based on suppression of lysine modiﬁcation, as
shown in the legend. Only inhibition levels greater than 50% are considered to be meaningful. Values lower than 35% fall in the range of sample to sample
variability (CVs typically 20%). Proteins were initially clustered based on inhibition values for lysates containing 10 μM of inhibitor 1, and then ranked
according to the extent of inhibition measured at 100 μM concentration. Codes for proteins discussed in the text: ASNS–asparagine synthetase;
NMNAT3–nicotinate-nucleotide adenylyltransferase; ASS1–argininosuccinate synthetase; KARS–lysyl-tRNA synthetase; CMPK1–UMP-CMP kinase 1;
MVK–mevalonate kinase; CMPK2–UMP-CMP kinase 2; AK1–adenylate kinase isoenzyme 1. A complete set of protein codes and chemoproteomic proﬁling
data is provided elsewhere (Supplementary Data 1)
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-019-0587-z
4 COMMUNICATIONS BIOLOGY |           (2019) 2:345 | https://doi.org/10.1038/s42003-019-0587-z | www.nature.com/commsbio
chloride54. Importantly for structure-based inhibitor discovery,
the synthetase site in the C-terminal domain, which is composed
of sixteen α-helices and ﬁve β-strands, is well resolved (Fig. 3b).
We also observed density consistent with a bound HEPES
molecule from the crystallization buffer in this domain, which
hydrogen bonds to the Asp-334 side chain and water molecules in
a network that also involves conserved residues Asp-400 and Arg-
403 (Fig. 4a, b). Residues in the synthetase active sites of human
ASNS and AS-B are highly conserved (Supplementary Fig. 7)
except that Val-272 and Met-333 in the bacterial form of the
enzyme are replaced by Ile-287 and Ile-347. Superimposing the
human and bacterial structures conﬁrms that the two synthetase
active sites are almost identical (Fig. 4c and Supplementary
Fig. 8). The Arg-403 side chain, however, adopts different con-
formations, presumably because AMP is not present in the syn-
thetase site. Interesting structural differences in the
intramolecular tunnel connecting the two active sites are also
observed for human ASNS and AS-B (Supplementary Fig. 9).
Asparagine synthetase deﬁciency (ASD) linked variants. Having
the crystal structure of human ASNS in hand offers an oppor-
tunity to map the locations of mutations in 15 residues that have
been identiﬁed in patients with asparagine synthetase deﬁciency
(ASD) (Fig. 5)2. Three of these mutational locations are in the N-
terminal domain although, of these, only the Arg-48 side chain is
positioned such that it could interact directly with the L-gluta-
mine substrate in the glutaminase active site. Substituting other
amino acids in this position might therefore impact the steps
leading to ammonia formation. The remaining sites, which are
mainly located in the C-terminal domain, can be clustered into
four groups (Supplementary Table 1). None of these residues,
b
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Fig. 3 X-ray crystal structure of human ASNS and the glutaminase active site. a Cartoon representation of the asymmetric unit of the human ASNS crystal
structure and a close-up view of the disulﬁde bond connecting the N-terminal domains of the ASNS monomers and the electron density surrounding this
region (gray mesh, contoured at 0.5 σ). The N- and C-terminal domains are colored teal and tan, respectively, and the atoms in the disulﬁde bond joining the
monomers are rendered as spheres. Carbon atoms in the DON moiety and the HEPES molecule present in the synthetase active site are shown as cyan and
purple spheres, respectively, and the bound chloride ion is drawn as a green sphere. Atom coloring scheme: C, cyan; N, blue; O, red; S, yellow. b Cartoon
representation of the human ASNS monomer. The domain and atom coloring scheme is identical to that used in (a). c Close-up of DON-modiﬁed Cys-
1 showing the hydrogen bonding interactions between the DON moiety (cyan) and residues in the glutaminase active site. Electron density for DON,
contoured at 0.5 σ, is rendered as a mesh. d Location of the glutaminase site at the domain/domain interface of human ASNS. Residues are identiﬁed using
standard one-letter codes and are numbered from the N-terminal residue (Cys-1)
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however, seem to be positioned adjacent to L-aspartate or ATP in
the synthetase active site. How these mutations exert their bio-
logical effects therefore remains unclear, although these might
include altered catalytic activity due to changes in dynamical
properties55, increased turnover or thermostability of the ASNS
variant, or the interaction of ASNS with other proteins within the
cell. Based on the ASNS structure we generated the T336I and
F361V ASNS variants and assayed their glutamine-dependent
activities relative to that of the WT enzyme by measuring MgPPi
production (see Supplementary Information). The mutation at
Thr-336, a Group IV residue (Supplementary Table 1), which is
highly conserved across all the kingdoms (Supplementary Fig. 7),
was chosen because it is located at the surface of the C-terminal
synthetase active site. Similarly, Phe-361, a Group II residue
(Supplementary Table 1), was of interest because it is located in
the interior of the C-terminal domain at a distance of 7.2 Å from
the chloride-binding site. In addition, Phe-361 is conserved in
mammalian asparagine synthetases but is replaced by leucine in
the glutamine-dependent plant and bacterial ASNS homologs
(Supplementary Fig. 7). Although glutamine-dependent synthe-
tase activity is almost abolished in the T336I ASNS variant,
replacing Phe-361 by valine gives an ASNS variant showing a
two-fold increase in activity relative to WT enzyme (Supple-
mentary Fig. 10). It is possible that shrinking the Phe-366 side
chain may impact structural packing within the C-terminal
domain of the enzyme or binding of the chloride anion.
These ﬁndings support the idea that some of the ASD-linked
changes might perturb asparagine-related metabolism. The
apparent involvement of ASNS in neurological development
implies that clinically useful ASNS inhibitors against metastasis
must not cross the blood-brain barrier or be restricted to use in
adults. Conversely, ASNS inhibitors capable of crossing the
blood-brain barrier might have clinical utility in treating ASD-
linked neurological disorders arising from ASNS variants with
enhanced catalytic activity.
Computational studies of inhibitor binding to human ASNS.
Kinetic measurements show that 1 is competitive with respect to
ATP (the ﬁrst substrate to bind in the pathway leading to
asparagine formation) and can bind to the DON-modiﬁed form
of human ASNS21. Both of these observations are consistent with
the idea that ASNS inhibitor 1 binds within the synthetase active
site of the enzyme (Fig. 4). Extensive crystallization trials, how-
ever, failed to yield crystals of the inhibitor bound to either DON-
modiﬁed or WT human ASNS. Functionalized sulfoximines are
stable to hydrolysis56, however, and the 1H NMR spectrum of 1 is
unchanged over a period of 19 days in the crystallization buffer.
Given that epimers 1a and 1b cannot be separated by column
chromatography, we carried out computational studies on models
of human ASNS bound to either 1a or 1b in which Cys-1 was
present as the unmodiﬁed amino acid (Fig. 6a). For these calcu-
lations, missing loops in the human ASNS structure, together
with residues 534–546 located in the C-terminal tail, were built
using the Modeller57 and Chimera58 software packages, and the
conformational properties of these regions were validated with
the Discrete Optimized Protein Energy protocol59. As a result,
only the last 14 residues (547–560) of the enzyme were absent in
this model (see Supplementary Information). We then positioned
MgPPi within the ASNS synthetase site above a conserved
pyrophosphate-binding loop60 in an identical orientation to that
seen in the X-ray crystal structure of the evolutionarily related
enzyme GMP synthetase51. MgPPi was included in the model
structure because it is the last product released during turnover16
and is therefore present in the enzyme when ammonia reacts with
the β–aspartyl-AMP intermediate. In silico docking61 was used to
position β–aspartyl-AMP (Fig. 1a) and each of the epimers 1a
and 1b into the MgPPi/ASNS complex. The resulting three model
complexes were next placed in a box of water molecules and
subjected to molecular dynamics (MD) simulations (100 ns)
(see Supplementary Information).
An extensive series of non-covalent interactions between
β–aspartyl-AMP and the enzyme were observed in the equili-
brated β–aspartyl-AMP/MgPPi/ASNS complex (Supplementary
Fig. 11a). For example, the phosphate moiety of this reactive
intermediate forms an electrostatic interaction with the side chain
of Lys-466, a conserved residue (Supplementary Fig. 7) that is
essential for catalytic activity in AS-B62. In addition, the 2′-OH
group on the ribose ring hydrogen bonds to the side chain of Ser-
362, consistent with the fact that dATP is not a substrate for the
enzyme. At the other end of the intermediate, the α-amino group
of β–aspartyl-AMP forms a salt bridge with the side chain of Asp-
367 and the α-carboxylate interacts with Glu-364 via a bridging
water molecule. To our knowledge, neither of these residues has
been altered previously by site-directed mutagenesis even though
both are conserved within known asparagine synthetases
(Supplementary Fig. 7). A similar set of interactions to those
seen in the β–aspartyl-AMP/MgPPi/ASNS complex were found in
MD trajectories of the model 1a/MgPPi/ASNS and 1b/MgPPi/
ASNS complexes. Importantly for future inhibitor discovery
Table 1 Crystallographic data collection and reﬁnement
statistics
Data collection
Beamline Diamond i04
Wavelength (Å) 0.9795
Resolution range (Å) 33.65–1.85 (1.88–1.85)
Space group P21
Unit cell (a, b, c, α, β, γ) 64.7 Å, 83.52 Å, 110.29 Å, 90°,
90.65°, 90°
Total reﬂections 339,772 (16,876)
Unique reﬂections 100,002 (4932)
Multiplicity 3.4 (3.4)
Completeness (%) 99.8 (99.9)
Mean I/σ (I) 9.7 (1.3)
CC half 0.996 (0.512)
Rmerge 0.087 (0.794)
Rpim 0.067 (0.624)
Reﬁnement
Rfactor 0.178
Rfree 0.226
RMSD bonds (Å) 0.0119
RMSD angles (°) 1.488
No. of non-H atoms
Protein 8259
Ligands/metal ions 68
Water molecules 551
Protein residues 1018 (2 chains; A and B)
Average B factors (Å2)
Main chain 31
Side chains 39
Ligands/metal ions 30
Water molecules 31
Ramachandran favored/
allowed (%)
97.02/2.78 (Phe399 is an outlier
on both chains)
Molprobity score 0.87, 100th percentile (N= 12654,
1.85 ± 0.25 Å)
Crystallization conditions: Proplex E9, 0.2M sodium chloride, 0.1 M Hepes buffer pH 7.5 and
12% PEG 8000. Data collected on 10-07-1016 on MX12788-32 and processed with xia2 -3d
pipeline. Data for the highest-resolution shell are given in parentheses. Note that Rmerge= Σhkl Σi
| Ii – Im|/Σhkl Σi Ii and Rpim= Σhkl√1/n− 1Σi=1 | Ii− Im|/Σhkl Σi Ii, where Ii and Im are the observed
intensity and mean intensity of related reﬂections, respectively.
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efforts, the positively charged amino group of both 1a and 1b is
preferentially bound in a pocket deﬁned by the side chains of Glu-
364, Asp-367, and Asp-400 (Fig. 5c). Protein/ligand hydrogen
bonds are also formed between 1a or 1b and Ser-362, Gly-363,
and Ile-287. In addition, bound water molecules are predicted to
mediate interactions between the functionalized methylsulfox-
imines and residues Asp-261, Asp-294, Gly-363, and Gly-364
(Supplementary Fig. 11).
Free energy perturbation (FEP/REST2) calculations63,64
(see Supplementary Information) were performed to obtain
estimates of the free energy difference between the functionalized
methylsulfoximines 1a and 1b within the synthetase active site of
human ASNS (ΔGprotein) and in water (ΔGwater). Using these
values in a thermodynamic cycle (Fig. 5b)65 gives an estimate of
−10.2 kJ mol−1 for (ΔGdiss (1a)− ΔGdiss(1b)) (see Supplementary
Information), meaning that diastereoisomer 1b has at least 60-
fold greater afﬁnity for ASNS than 1a at 25 °C. This difference is
consistent with the expected value based on qualitative arguments
from kinetic data21,22.
A negatively charged cluster underlies binding selectivity. We
sought to test these computational models by examining the effect
of site-speciﬁc mutations on the ability of ASNS inhibitor 1 to
bind to human ASNS. Two sets of site-speciﬁc mutations were
selected on the basis of the intermolecular interactions observed
in the computational models of the 1a/MgPPi/ASNS (Fig. 6c)
and 1b/MgPPi/ASNS complexes (Fig. 6d). Thus, removing the
D400
(D348)
R403
(R387)
D367
(D351)
Y373
(Y353)
I347
(M332)
I287
(V272)
M344
(M329)
L255
(L232)
D294
(D279)S262(S239)
S263
(S240)
L260
(L237) R464(R447)
D261
(D238)
K444
(K429)
S257
(S234)
L256
(L233)
A286
(A271)
E364
(E348)
S363
(S346) F285
(F270)
b
Y375
Y373
F399
D334
T337D400
R403
E368
c
a
Fig. 4 Structural features of the synthetase active site and putative inhibitor binding pocket. a Cartoon rendering of DON-modiﬁed human ASNS and the
C1A AS-B variant (1CT9)42 containing a molecule of HEPES (C: purple spheres) and AMP (C: magenta spheres) in the two synthetase active sites,
respectively. The N- and C-terminal domains of human ASNS are colored teal and tan, respectively, while the cognate domains in AS-B are colored green
and pale yellow, respectively. b Close-up view of the network of intermolecular interactions between bound HEPES and residues/water molecules in the
synthetase active site of human ASNS. Hydrogen bonds are shown as yellow dashed lines and waters by red spheres. c Residue conservation in the
synthetase active sites of human ASNS and AS-B with side chain carbons of the two homologs being colored tan and pale yellow, respectively. Carbon
atoms in the AMP molecule observed in the AS-B synthetase site are rendered in magenta. Waters are rendered as red spheres. Residues in both
structures are identiﬁed using one-letter codes and are numbered from the N-terminal residue (Cys-1). AS-B residue numbers are given in parentheses
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-019-0587-z ARTICLE
COMMUNICATIONS BIOLOGY |           (2019) 2:345 | https://doi.org/10.1038/s42003-019-0587-z | www.nature.com/commsbio 7
Glu-364 side chain was anticipated to weaken the binding of
diastereoisomer 1b to the enzyme with little, or no, effect on
diastereoisomer 1a. Assuming that 1b has greater afﬁnity for the
enzyme, as suggested by the FEP calculations, the mixture of
epimers 1a and 1b was anticipated not to inhibit Glu-364 ASNS
variants with nanomolar afﬁnity. Similarly, removing the nega-
tively charged Asp-367 side chain was expected to reduce the
afﬁnity of 1a rather than 1b, meaning that the epimeric mixture
1a and 1b would exhibit the same level of inhibition when
incubated with Asp-367 ASNS variants.
We expressed and puriﬁed ASNS variants in which Glu-364
was replaced by alanine (E364A) or glutamine (E364Q), and Asp-
367 was replaced by alanine (D367A) or asparagine (D367N).
Kinetic assays monitoring MgPPi formation21,22 show that the
E364A, E364Q, and D367A ASNS variants are inactive when
incubated at pH 8.0 with L-aspartate, ATP, and ammonium
chloride as nitrogen source. Efforts to characterize the afﬁnity of
the ASNS inhibitor 1 for the three inactive ASNS variants using
isothermal calorimetry have been unsuccessful, perhaps because
of the slow off-rate of ASNS inhibitor 1 from the E*I complex21.
These data, however, reveal the importance of Glu-364 in binding
and/or catalysis as predicted on the basis of the computational
models. Moreover, the D367N ASNS variant exhibits reduced
ammonia-dependent activity relative to that of WT enzyme when
incubated at pH 8.0 with L-aspartate, ATP and ammonium
chloride (Supplementary Fig. 12). The D367N ASNS variant is
also inhibited when incubated with 1 μM ASNS inhibitor 1
although MgPPi production is stimulated at short reaction times
under these conditions. In addition, inhibition of the D367N
ASNS variant is seen at longer times than those at which the
inhibitor abolishes ammonia-dependent activity of the WT
enzyme (Supplementary Fig. 12). Nevertheless, slow-onset
inhibition is still seen for the D367N ASNS variant after 200 sec,
perhaps implying that removing the negative charge decreases the
isomerization rate of the initial ASNS/inhibitor complex
compared to that of WT enzyme. The altered inhibition kinetics
support our prediction that epimer 1b has higher afﬁnity for the
synthetase site because of its interaction with the Glu-364
side chain.
Structure-based insights into ASNS inhibitor selectivity. The
synthetase domain of human ASNS is evolutionarily related to
similar AMP-forming domains in a large number of other pro-
karyotic and eukaryotic enzymes60. As part of trying to understand
the pattern of binding selectivity observed in the chemoproteomic
proﬁling assays (Fig. 2), we identiﬁed 128 AMP-forming domains
in other protein structures with signiﬁcant structural similarity to
the synthetase domain (residues 222-533) (http://ekhidna2.
biocenter.helsinki.ﬁ/dali/)66 (Supplementary Data 2). Only 48 of
the 128 structural neighbors are present in the human proteome,
however, and crystal structures have been deposited for only 10 of
these proteins (Supplementary Data 2). Almost all of these
enzymes employ ATP, or the structurally similar co-factors SAM
and NAD+, as substrates, with uroporphyrinogen-III synthase67
being an interesting exception. Importantly, transcriptome
expression studies show that 47 of these 48 proteins are likely to be
present in HCT-116 cell lysates (Supplementary Fig. 1), and we
identiﬁed peptides from 10 of these proteins in our chemopro-
teomic proﬁling assay (Supplementary Data 1). Mechanistic con-
siderations suggest that ASNS inhibitor 1 might exhibit off-target
binding to glutamine-dependent NAD+ synthetase68, GMP
synthetase32,51, argininosuccinate synthetase69, and FMN adeny-
lyltransferase (NMAT1)70. Support for this idea is provided by the
fact that these human enzymes have AMP-forming domains with
the highest structural similarity to the synthetase domain of ASNS
(Supplementary Data 2). Of these enzymes, as discussed above,
ASNS inhibitor 1 exhibits off-target binding with ASS1 at 100 μM
concentration (Supplementary Fig. 3), but there is no evidence to
indicate that such an interaction takes place with GMP synthetase
in HCT-116 cell lysates (Supplementary Data 1). Tryptic peptides
from the ATP-binding sites of glutamine-dependent NAD+ syn-
thetase and FMN adenylyltransferase, however, are not observed in
the chemoproteomic proﬁling assays even though both proteins
are expressed based on transcriptome data (Supplementary Fig. 1).
As a result, the extent to which ASNS inhibitor 1 interacts with
these two proteins is unresolved by these chemoproteomic proﬁl-
ing assays.
In an effort to place our ﬁndings on a structural foundation, we
overlaid the conserved PP-loop motifs of our 1b/MgPPi/ASNS
model complex and the X-ray crystal structures of human ASS1
and GMP synthetase (Fig. 7a). Even without extensive reposition-
ing of residue side chains, these superimposed structures provide
a qualitative picture of active site similarities and differences that
might underlie the binding selectivity of ASNS inhibitor 1. All
three enzymes share a common loop motif for binding MgPPi
released during formation of the adenylated intermediate (Fig. 7a)
and make very similar intermolecular interactions with the AMP
moiety of the ASNS inhibitor 1b (Fig. 7b). Differences in inhibitor
binding afﬁnity seem to be associated with a cluster of negatively
charged side chains (Fig. 4c) in the ASNS synthetase domain
(Glu-364, Asp-367, and Glu-368) that bind the protonated amino
group present in ASNS inhibitor 1 on the basis of computational
modeling (Fig. 7c). This negatively charged pocket is absent in the
active sites of argininosuccinate synthetase (Fig. 7d) and GMP
synthetase (Fig. 7e). These data suggest that the residues Glu-364,
Asp-367, and Glu-368 deﬁne the selectivity of ASNS inhibitor 1
towards human ASNS. If this is the case, second generation ASNS
R48
A5
L144
L246
G288
T336
R339F361
A379
Y397
R406
S479
V488
Fig. 5 Locations of mutated residues in human ASNS that are associated
with asparagine synthetase deﬁciency. a Cartoon representation of the X-
ray crystal structure of human ASNS showing the locations of the 15
mutational sites (Ala-5, Arg-48, Leu-144, Leu-246, Gly-288, Thr-336, Arg-
339, Phe-361, Ala-379, Tyr-397, Arg-406, Ser-479, Val-488, Trp-540, and
Arg-549) that have been identiﬁed in patients with asparagine synthetase
deﬁciency. The side chains of mutated residues are rendered as spheres.
Colored regions indicate sites that can be classiﬁed as Group I (red), Group
II (yellow), Group III (green), and Group IV (blue) (Supplementary Table 1)
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inhibitors must maintain the key electrostatic interactions with
this negatively charged pocket if binding speciﬁcity is to be
realized. In addition, given that the conserved residue Glu-364 is
required for catalytic activity, it seems unlikely that resistance
mutations could arise at this position in the ASNS synthetase
active site.
Discussion
This work establishes the feasibility of obtaining ASNS inhibitors
that exhibit considerable selectivity when present at low, or sub-
micromolar concentrations in cells despite the existence of other
ATP-utilizing enzymes possessing homologous catalytic domains
to ASNS. Access to the X-ray structure of human ASNS, coupled
with chemoproteomic proﬁling, has also allowed us to identify a
cluster of negatively charged side chains in the ASNS synthetase
domain (Glu-364, Asp-367, and Glu-368) that plays a key role in
deﬁning the binding selectivity of ASNS inhibitor 1. These results
will facilitate the discovery of new small-molecule ASNS inhibi-
tors, which can be used (i) to probe the role of L-asparagine
production in metastatic progression, and (ii) as agents to control
either metastasis and/or tumor growth in animal-based
experiments.
Methods
Chemical synthesis. Details of the synthetic procedures used to obtain the
sulfoximine-based inhibitor 1 have been published elsewhere21.
NMR-based stability studies of ASNS inhibitor 1. A solution of 100 mM sodium
HEPES buffer, pH 7.5, containing 200 mM NaCl (540 µL) was added to 10 mM
Tris-HCl buffer, pH 8, containing 100 mM NaCl (420 µL) and the mixture was
diluted with distilled water (120 µL). An aliquot of this buffer solution (480 µL) was
then mixed with 50 mM ASNS inhibitor 1 dissolved in water (20 µL), and the
resulting solution was transferred to an NMR tube together with a sealed capillary
containing 5.5 mM dimethylmalonate dissolved in D2O (60 µL). The ﬁnal con-
centration of inhibitor 1 was 1.8 mM. 1H NMR spectra were then recorded over a
period of 19 days on an Avance-III HD 500MHz spectrometer. The water signal
was suppressed using excitation sculpting with gradients71. No changes in the
peaks arising from inhibitor 1 were observed during this time even though the
sample was stored at room temperature.
Chemoproteomic proﬁling. The desthiobiotin-adenosine triphosphate-acylpho-
sphate probe 3 (ATP probe) was synthesized as described previously24. An HCT-
116 cell pellet was lysed by sonication in lysis buffer (50 mM sodium HEPES, pH
7.5, containing 150 mM NaCl, 0.1% (v/v) Triton X-100 and phosphatase inhibitors
a
c d
b
ΔGprotein
ΔGwater
ΔGdiss (1a)
R-form
S-form
R403
A340
S362
E364
G365
G363
E368
Y373
D367
S366
K444
K444
K466 R448
G259
D294
S257 A286
l287S362
E364
R403D400
E368
S366
D367
R448
D261 S262
l287
Y373
ΔGdiss (1b)
Fig. 6 Computational models of the functionalized methylsulfoximines 1a and 1b bound within the synthetase active site of the human ASNS/MgPPi
complex. a Surface representation of human ASNS showing the location of the putative inhibitor binding pocket within the synthetase active site. The N-
and C-terminal domains of the enzyme are colored in teal and tan, respectively. Close-up views show the positions of the functionalized
methylsulfoximines 1a (magenta) and 1b (yellow) relative to the bound inorganic pyrophosphate (orange) and Mg2+ (gray) ions in each model complex.
b Thermodynamic cycle used to estimate the difference in binding free energy (ΔGdiss(1a)–ΔGdiss(1b)) of the diastereoisomers 1a and 1b computed from
ΔGprotein–ΔGwater values obtained by free energy perturbation calculations. Both ΔGdiss(1a) and ΔGdiss(1b) have positive values since they describe
dissociation of each ASNS/ligand complex. c Close-up of 1a showing the non-covalent interactions with synthetase active site residues and water
molecules in the computational model. d Close-up of 1b showing the non-covalent interactions with synthetase active site residues and water molecules in
the computational model
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[Cocktail II AG Scientiﬁc #P-1518]). The samples were then centrifuged in an
Eppendorf 5424 R microcentrifuge at 16,200 xg for 15 min at 4 °C and the
supernatant collected for probe labeling. Five microliters ofthe sulfoximine-based
inhibitor 1 was added from 100× stock solutions in dimethyl sulfoxide (DMSO) to
445 μL of lysate in duplicate. DMSO (5 µL) was added in control samples. After
15 min incubation, 50 µL of a 10x aqueous solution of the ATP probe was added to
each sample to give a ﬁnal probe concentration of 5 µM, and samples were incu-
bated with probe for an additional 10 min. Samples were prepared for mass
spectrometric (MS) analysis following standard procedures38. Brieﬂy, probe-labeled
lysates were denatured and reduced in 6M urea, 10 mM dithiothreitol (DTT) at 65
°C for 15 min), alkylated (40 mM Iodoacetamide, 37 °C, 30 min), and gel ﬁltered
(Biorad Econo-Pac® 10 G) into 10 mM ammonium bicarbonate, containing 2M
urea and 5 mM methionine. The desalted protein mixture was digested with trypsin
(0.015 mgmL−1) for 1 hr at 37 °C, and desthiobiotinylated peptides captured using
12.5 μL high-capacity streptavidin resin (Thermo Scientiﬁc). Captured peptides
were then washed extensively, and probe-labeled peptides eluted from the strep-
tavidin beads using two 35-μL washes of a 50% (v/v) CH3CN/water mixture
containing 0.1% (v/v) triﬂuoroacetic acid (TFA) at room temperature. The
resulting samples were then analyzed on Thermo LTQ Velos ion trap mass spec-
trometers coupled with Agilent 1100 series micro-HPLC systems with auto-
samplers72. For signal extraction and quantitation, up to four ions were typically
selected based on their presence, intensity, and correlation to the reference MS/MS
spectrum. The resulting chromatographic peaks in each run were then integrated
and the integrated peak areas used to determine % inhibition values relative to
control samples (Supplementary Data 1).
Putative interaction of ASNS inhibitor 1 with UMP-CMP kinase 1 (CMPK1).
Given that chemoproteomic proﬁling showed that ASNS inhibitor 1 binds human
CMPK136, which has a completely different fold to the synthetase domain of
human ASNS, we built a model of how the ASNS inhibitor 1 might interact with
the kinase, making the reasonable assumption that binding takes place within the
ATP-binding site. Unfortunately, the X-ray crystal structure of human CMPK1
lacks a bound ligand73, and so we superimposed the ASNS inhibitor 1a on the
bound ATP in the active site of the homologous enzyme in Dictyostelium dis-
coideum37 to obtain an initial model of the 1a/CMPK1 complex (Supplementary
Fig. 2). Preliminary MD simulations of this complex show that if the adenosyl
group of 1a binds to the solvent accessible ATP-binding site then the protonated
amino group of the inhibitor prefers to be solvated within the aqueous environ-
ment. These calculations also suggest that there are no speciﬁc interactions between
the sulfoximine moiety and the protein. As a result, we speculate that both epimers
1a and 1b could bind to CMPK1. Additional studies, which lie outside the scope of
this paper, will be needed to determine exactly how ASNS inhibitor 1 is bound
by CMPK1.
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PP-loopAsparagine synthetaseGMP synthaseArgininosuccinate synthase
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Fig. 7 Structural basis for the binding selectivity of ASNS inhibitor 1b. a Alignment of the conserved SGGxD loops (PP-motifs) in argininosuccinate
synthetase (2NZ2)69 (green), GMP synthetase (2VXO)32 (cyan) and the 1b/MgPPi/ASNS computational model (tan). Circles show the location of the PP-
motif in the AMP-forming domain of the three enzymes. Carbon atoms in methylsulfoximine 1b are colored yellow. Color scheme: N, blue; O, red; P,
orange; Mg, gray. b Superimposition of the homologous AMP-binding sites in argininosuccinate synthetase (C: green), GMP synthetase (C: cyan) and the
1b/MgPPi/ASNS computational model (C: tan) showing the similarity of residues in this region. ASNS residues are labeled using standard one-letter codes
and are numbered from the N-terminal residue (Cys-1). c Close-up of putative intermolecular interactions between the protonated amino group of 1b and
human ASNS synthetase active site residues (C: tan). ASNS residues are labeled using standard one-letter codes and are numbered from the N-terminal
residue (Cys-1). d Close-up of argininosuccinate synthetase residues (C: green) surrounding the protonated amino group of 1b assuming that the ASNS
inhibitor binds to the enzyme in a similar pose to that modeled for human ASNS. Argininosuccinate synthetase residues are labeled using standard one-
letter codes and are numbered from the X-ray crystal structure69. e Close-up of GMP synthetase residues (C: cyan) surrounding the protonated amino
group of 1b assuming that the ASNS inhibitor binds to the enzyme in a similar pose to that modeled for human ASNS. GMP synthetase residues are labeled
using standard one-letter codes and are numbered from the X-ray crystal structure32. The protein orientations in c–e are aligned to aid structural
comparisons
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Expression and puriﬁcation of recombinant human ASNS and the T336I,
F361V, E364A, E364Q, D367A, and D367N ASNS variants. The open reading
frame (ORF) of human ASNS containing a Tobacco Etch Virus protease (TEV
protease)74 site (ENLYFQS) followed by a C-terminal 10-histidine tag (His10) was
codon-optimized, synthesized, and sub-cloned into the EcoRV site of a pUC57
vector by GenScript (Piscataway, NJ), to give the pUC57-BamHI-hASNS-TEV-
His10-HindIII vector (Supplementary Data 3). The BamHI-HindIII DNA fragment
from this vector was then sub-cloned into the same sites in a pFL vector75, yielding
the pFL-hASNS-TEV-His10 vector (pYT1215), which was then used to generate a
recombinant baculovirus expressing C-terminally His10-tagged human ASNS fol-
lowing published protocols45. For large-scale expression, frozen stocks were gen-
erated and stored under liquid nitrogen. Sf9 cells were obtained from Expression
Systems (Davis, CA), and were maintained in ESF921 medium (Expression Sys-
tems) at 27 °C in shaker ﬂasks. The expression of human ASNS in Sf9 cells was
optimized using the TEQC method45. Brieﬂy, a 1 L culture of Sf9 cells (1.5 × 106
cells mL−1) was infected with the baculovirus expressing recombinant human
ASNS with MOI= 4.0, the infected cells were then incubated at 27 °C for 96 h
before being harvested by centrifugation and frozen in liquid N2. The resulting
pellet was then stored at −80 °C until lysed in 50 mM Tris-HCl buffer, pH 8.0,
containing 500 mM NaCl. After cell lysis and centrifugation, the supernatant was
loaded onto a 5 mL GE HisTrap HP column (GE Healthcare) that was pre-
equilibrated in 50 mM Tris-HCl buffer, pH 8.0, containing 500 mM NaCl using
ÄKTAprime plus FPLC (GE Healthcare) and the C-terminally His10-tagged,
recombinant human ASNS was eluted from the column with increasing gradient
(0–100%) of buffer containing 50 mM Tris-HCl, 500 mM imidazole, 500 mM NaCl,
pH 8.0. The fractions containing human ASNS were conﬁrmed by SDS-PAGE and
combined. The resulting solution was exchanged to buffer containing 10 mM Tris-
HCl buffer, pH 8.0, containing 100 mM NaCl using a PD-10 column (GE
Healthcare). Mass spectrometry on the as-puriﬁed intact protein conﬁrmed that
correctly processed, full-length enzyme had been puriﬁed. For crystallography, the
C-terminal His10-tag was removed using the S219P variant of TEV protease (25:1
molar ratio His10-tagged human ASNS:TEV protease) and dialyzed at 4 °C over-
night against 25 mM Tris-HCl buffer, pH 8.0, containing 250 mM NaCl and 5 mM
DTT. The sample was then ﬂowed over the nickel column again to remove
uncleaved His10-tagged hASNS and the protease, and the ﬂow-through was
exchanged using a PD-10 column (GE Healthcare) into 10 mM Tris-HCl
buffer, pH 8.0, containing 100 mM NaCl before the enzyme was concentrated to
6 mgmL−1.
In a similar manner, codon-optimized DNAs (Supplementary Data 3)
containing mutations encoding the T336I, F361V, E364A, E164Q, D367A, and
D367N ASNS variants containing a TEV protease site74 followed by a C-terminal
10-histidine tag (His10) were synthesized and introduced into pFL-hASNS-TEV-
His10 vector (pYT1215) by GenScript (Piscataway, NJ) to give vectors pYT1678
(T336I), pYT1690(F361V), pYT1668(E364A), pYT1667(E364Q), pYT1670
(D367A), and pYT1669(D367N). These transfer vectors were then used to generate
baculoviruses that permitted the expression and puriﬁcation of each human ASNS
variant following the same protocol as that outlined above for the untagged, wild-
type enzyme.
Expression and puriﬁcation of recombinant human argininosuccinate syn-
thetase (ASS1). The open reading frame (ORF) of human ASS containing an N-
terminal His10 tag followed by a 3 C protease76 site was codon-optimized, syn-
thesized, and sub-cloned into the EcoRV site of the pUC57 vector by GenScript
(Piscataway, NJ, USA) to give the pUC57-BamHI-hASS-HindIII plasmid (Sup-
plementary Data 3). The BamHI–HindIII DNA fragment from each vector was
then sub-cloned into the same sites in the pKL-10His-3C vector77 to give the pKL-
10His-3C-hASS (pYT1704) transfer vector. After generation of the baculovirus
using this transfer vector, recombinant, N-terminally tagged WT human ASS1 was
expressed in Sf9 insect cells using a similar protocol to that described above for WT
human ASNS. Cells containing the recombinant enzyme were suspended in 50 mM
sodium phosphate buffer, pH 7.5, containing 300 mM NaCl, 10 mM imidazole,
5 mM 2-mercaptoethanol, 0.01% NP-40 and 1x protease inhibitor cocktail (PI).
After cell lysis at 4 °C for 30 min, the resulting suspension was centrifuged (35,000
rpm) at 4 °C for 45 min, and the supernatant was incubated with His-Select nickel
afﬁnity resin (Sigma) at 4 °C for 1 h. Unbound material was removed by washing
the resin with lysis buffer without PI. The recombinant human ASS1 could then be
eluted using lysis buffer without PI that contained 500 mM imidazole. Elution
fractions were concentrated (Vivaspin, 10000 MW cutoff) to a volume of
approximately 1 mL and dialyzed overnight at 4 °C against 50 mM sodium HEPES
buffer, pH 7.5, containing 300 mM NaCl, 10% (v/v) glycerol and 2 mM DTT. The
sample was then dialyzed at 4 °C against 50 mM sodium HEPES buffer, pH 7.5,
containing 300 mM NaCl, 10% (v/v) glycerol and 2 mM TCEP. The resulting
sample, which had a ﬁnal concentration of 0.4 mg mL−1, was then stored at
−80 °C.
Kinetic characterization of human ASS1. The activity of recombinant, WT
human ASS1 was assayed by measuring the rate of inorganic pyrophosphate
(MgPPi) production using an enzyme-coupled continuous assay (pyrophosphate
reagent P7275, Sigma-Aldrich)78. In these experiments, assay mixtures contained
0.5 mM ATP, 0.2 mM L-aspartate, ASS1 (4 μg), pyrophosphate reagent (350 μL),
and 2 mM KCl dissolved in 100 mM Tris-HCl buffer, pH 7.5, containing 5 mM
MgCl2 and ASNS inhibitor 1 (as a 1:1 mixture of diastereoisomers 1a and 1b) at 0
μM, 10 μM, or 100 μM concentration (1 mL total volume). Reactions were initiated
at 37 °C by the addition of L-citrulline, to a ﬁnal concentration of 0.2 mM, and
NADH consumption was monitored spectrophotometrically at 340 nm over a
period of 20 min using a Varian Cary® 50 UV-visible spectrometer (Agilent
Technologies) (Supplementary Fig. 3). All kinetic assays were performed in tri-
plicate. A standard curve to convert absorbance units into MgPPi concentration
was constructed using known amounts of MgPPi dissolved in 100 mM Tris-HCl
buffer, pH 7.5, containing 5 mM MgCl2, 0.2 mM L-aspartate, 0.2 mM L-citrulline,
and 2 mM KCl. The standard curve was unaffected by the presence of 100 μM
ASNS inhibitor 1.
Crystallization and structure solution of human ASNS. Prior to crystallization,
recombinant human ASNS (140 μL of a 6 mgmL−1 solution in 10 mM Tris-HCl
buffer, pH 8.0, containing 100 mM NaCl) was incubated with 20 mM 6-diazo-5-
oxo-L-norleucine (DON) (20 μL) at room temperature for 45 min to give the
DON-modiﬁed form of the enzyme (Supplementary Fig. 4)79. A solution of 20 mM
sodium pyrophosphate (20 μL) was then added to the DON-modiﬁed human
ASNS to give a stock solution. Automated sitting-drop crystallization trials were
carried out on a Hydra II Plus 1 crystallization robot using a 1:1 ratio of protein to
reservoir solution. A single crystal grew in conditions containing 0.2 M NaCl, 0.1 M
sodium HEPES buffer, pH 7.5, and 12% (w/v) PEG 8000 (ProPlex HT-96, Mole-
cular Dimensions) at 17 °C after a period of 3 weeks (Supplementary Fig. 5). This
crystal was harvested after 5 weeks and ﬂash cooled using liquid nitrogen in a cryo-
protectant comprising the crystallization conditions, plus an additional 25% (w/v)
ethylene glycol. Diffraction data were collected at Diamond Light Source beamline
i04 at 100 K, using a wavelength of 0.9795 Å. Data were processed using the 3d
module of the Xia2 pipeline80 revealing that the crystal belonged to the space group
P21 with unit cell dimensions of a= 64.7 Å, b= 83.52 Å, and c= 110.29 Å.
Molecular replacement was carried out in PHASER81, from within the CCP4i82
package, using the glutamine-dependent asparagine synthetase from Escherichia
coli (PDB:1CT9)41 as a search model. Reﬁnement of the initial model was carried
out in an iterative manner using REFMAC5 (ref. 83) combined with manual
rebuilding in Coot84. The resulting model, which contained 2 molecules of DON-
modiﬁed, human ASNS per asymmetric unit, 551 molecules of water, and 2
molecules of HEPES, was reﬁned to 1.85 Å resolution (Supplementary Fig. 6). The
MolProbity server85 was used to validate the structure, with the Ramachandran
plot showing that one residue (Phe-399) is a Ramachandran outlier on both chains.
The cognate residue in AS-B is also an outlier, suggesting that an unusual backbone
geometry is conserved in this area of the enzyme. All other residues were in
favorable or allowed areas of the Ramachandran plot. Coordinates have been
deposited in the Protein Data Bank under accession number 6GQ3.
Kinetic characterization of ASD-linked human ASNS variants. The speciﬁc
activity of the T336I and F361V ASD-linked ASNS variants was determined using
the EnzChekTM Pyrophosphate Assay (Molecular Probes). Brieﬂy, reaction was
initiated by addition of 0.1 μM enzyme to a reaction mixture containing 150mM
NaCl, 10mM MgCl2, 1 mM DTT, 10 mM L-glutamine, 10 mM L-aspartate, 5 mM
ATP, 0.2 mMMESG, 1 U mL−1 purine nucleoside phosphorylase, and 0.03 U mL−1
inorganic pyrophosphatase at 37 °C in 100mM EPPS buffer, pH 8.0. The activity
was monitored by measuring the absorption change at 360 nm using a Varian Cary®
50 UV-visible spectrometer (Agilent Technologies). A standard curve was deter-
mined using standard MgPPi solution diluted in a buffer solution of 100mM EPPS,
pH 8.0, containing 150mM NaCl, 10mM MgCl2, 1 mM DTT, 10 mM L-glutamine,
10 mM L-aspartate, 5 mM ATP, 0.2mM MESG, 1 U mL−1 purine nucleoside
phosphorylase, and 0.03 U mL−1 inorganic pyrophosphatase at 37 °C. The per-
centage activity of each variant was normalized against that of WT human ASNS
(Supplementary Fig. 10).
Molecular dynamics simulations of human ASNS, its complexes with the β-
aspartyl-AMP intermediate, and with the functionalized methylsulfoximines
1a and 1b. The X-ray crystallographic coordinates of DON-modiﬁed human ASNS
were used to build the initial model of the enzyme for simulations of the enzyme/
inhibitor complexes. Segments of missing residues and side chains were built using
Modeller57 and the Chimera GUI58. The conformational properties of these regions
were validated with the Discrete Optimized Protein Energy (DOPE) protocol59. All
amino acid residues introduced into the X-ray crystal structure were geometry
optimized with all other atoms constrained to their crystallographic coordinates.
This model was then energy minimized following standard protocols to remove
bad contacts, before being further reﬁned using the AMBER software suite86. Thus,
the complex was solvated in a truncated octahedral box (98 × 98 × 98 Å) of TIP3P87
water molecules together with eight Na+ ions. After assignment of ff14SB force
ﬁeld88 parameters, the system was energy minimized while constraining the
positions of the non-hydrogen protein atoms (500 kcal mol−1 Å−2). The
restraining force constant was then reduced (10 kcal mol−1Å−2), and the system
slowly heated to 300 K and equilibrated over a period of 2.4 ns in the NVE
ensemble with periodic boundary conditions. In these simulations, restraints were
placed on hydrogen atoms that were not involved in hydrogen bonds using the
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SHAKE89 algorithm. The temperature of the system in these equilibration simu-
lations was controlled using a Langevin thermostat90. A ﬁnal equilibration was
carried out in an NPT ensemble (300 K and 1 atm) for 15 ns. All MD simulations
employed a non-bonded cutoff of 12 Å.
This structure was then used as the basis for modeling the 1a/MgPPi/ASNS, 1b/
MgPPi/ASNS, and β–aspartyl-AMP/MgPPi/ASNS complexes by docking the
appropriate ligand into the synthetase active site. The initial positions of the ligands
were selected using procedures that we have described elsewhere21, with inorganic
pyrophosphate being positioned in an identical orientation above the SGGxD loop
to that observed in the X-ray crystal structure of GMP synthetase (PDB: 1GPM)51.
Each of these three structures and the free enzyme were then placed within an
orthorhombic box of explicit TIP3P water molecules. The box size was chosen so
that there was a 10 Å buffer distance in each dimension from any protein atom.
These four model systems were energy minimized, until a gradient threshold of
25 kcal mol−1 Å−1 was attained, and then equilibrated at 300 K using a series of
short MD simulations. The resulting models were then subject to 100 ns of MD
simulation in the NPT ensemble at a temperature of 300 K and a pressure of 1 atm
using the DESMOND91 software package with the OPLS-2005 all-atom force
ﬁeld92. In these simulations, hydrogen atoms were constrained using the SHAKE
algorithm89, and long-range electrostatic energies were computed by particle mesh
Ewald93 with a short-range cutoff of 12 Å for short-range Coulombic interactions.
Structures were sampled from the trajectory at 20 ps intervals (5000 frames per
simulation) analyzed using standard methods.
Free energy perturbation (FEP/REST2) estimates of the relative binding
afﬁnities of 1a and 1b. FEP/REST2 calculations63,64,94 were performed to obtain
estimates of the free energy difference between the functionalized methylsulfox-
imines 1a and 1b within the synthetase active site of human ASNS using the
algorithms implemented in the DESMOND38 software package and describing
atoms in 1a and 1b with the OPLS-2005 all-atom force ﬁeld39. Thus, the optimized
model of the 1a/MgPPi/ASNS complex was placed within an orthorhombic box
(12 Å buffer distance in each dimension from any protein atom) of explicit TIP3P
water molecules with sufﬁcient Na+ ions to neutralize the charge of the system.
Changing the conﬁguration about the sulfur atom in the ligand was accomplished
using 100 ns MD simulations at each of 12 λ values (1.0, 0.92, 0.83, 0.75, 0.67, 0.58,
0.42, 0.33, 0.25, 0.17, 0.08, 0.0) with the heavy atoms of the ligand (apart from those
of the adenosine moiety) being selected for enhanced sampling, as described
elsewhere63,64,94. These calculations gave an estimate for ΔGprotein of −10 ± 2.1 kJ
mol−1 based on the Bennett acceptance ratio95. Following a similar protocol, FEP/
REST2 calculations were performed to obtain estimates of the free energy differ-
ence between the functionalized methylsulfoximines 1a (λ= 0) and 1b (λ= 1)
when solvated in a box of explicit TIP3P water molecules. In these latter set of
calculations, the initial conformation of 1a was identical to that present in the
model of the 1a/MgPPi/ASNS complex. These calculations gave an estimate for
ΔGwater of −0.20 ± 0.17 kJ mol−1. As a result, the difference in binding free energies
of the two ligands is estimated to be −10.2 kJ mol−1, based on a standard ther-
modynamic cycle (Fig. 5b). As a result, one can write the following expression:
ΔGdiss 1að Þ  ΔGdiss 1bð Þ ¼ 2:303RT log10
Kd 1bð Þ
Kd 1að Þ
 
When R= 8.314 J mol−1 K−1 and T= 298.15 K, this yields a value of Kd 1bð ÞKd 1að Þ ¼ 63.
Examining predictions of the computational models by site-directed muta-
genesis. The activity of WT human ASNS and four ASNS variants (E364A,
E364Q, D367A, and D367N) was assayed by measuring the rate of MgPPi pro-
duction using a continuous assay employing the EnzChekTM Pyrophosphate Assay
(Molecular Probes) as described in detail elsewhere96. In these experiments, assay
mixtures contained 0.5 mM ATP, 5 mM L-aspartate 0.01 U mL−1 nucleoside
phosphorylase, 3 × 10−4 U mL−1 inorganic phosphatase, and 100 mM NH4Cl
dissolved in 100 mM EPPS buffer, pH 8.0, containing 10 mM MgCl2 and either
0 μM or 1 μM ASNS inhibitor 1 (as a 1:1 mixture of epimers 1a and 1b) (1 mL total
volume). Reactions were initiated at 25 °C by the addition of recombinant, WT
human ASNS (4 μg), and 2-amino-6-mercapto-7-methylpurine production was
then monitored spectrophotometrically at 360 nm over a period of 10 min. All
kinetic assays were performed in triplicate. Identical assay conditions were
employed in studies of the D367N ASNS variant except that L-aspartate was pre-
sent at a ﬁnal concentration of 50 mM and reactions were initiated by the addition
of recombinant enzyme (40 μg). A standard curve to convert absorbance units into
MgPPi concentration was constructed using known amounts of MgPPi dissolved in
50 mM EPPS buffer, pH 8.0, containing 50 mM L-aspartate, 200 mM NaCl and
2 mM TCEP. The standard curve was unaffected by the presence of up to 10 μM
ASNS inhibitor 1.
General note. The pH of all buffer solutions used in the following experimental
procedures was adjusted by the addition of either aq. HCl or aq. NaOH.
Statistics and reproducibility. The primary statistical analysis in the chemopro-
teomic proﬁling measurements is a determination of the signiﬁcance of inhibition
using the Student t-test. All datapoints for which 1 inhibits modiﬁcation of the
ATP-binding site by the reactive probe 3 to an extent that is greater than 35% are
considered signiﬁcant if p < 0.04. Control CVs are calculated using the expression
[(control std. deviation)/(average control signal)] * 100%. Estimates of the errors in
the free energy calculations are based on the Bennett acceptance ratio. Values for
percentage activities or steady-state kinetic parameters are calculated (mean ±
standard deviation) from triplicate measurements.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Atomic coordinates and structure factors for recombinant, DON-modiﬁed human ASNS
have been deposited in the Protein Data Bank with accession number 6GQ3. Coordinates
for the computational models of the 1a/MgPPi/ASNS, 1b/MgPPi/ASNS and β–aspartyl-
AMP/MgPPi/ASNS complexes, MD simulation trajectories and I/O ﬁles for the free
energy calculations, and raw data for protein puriﬁcation and kinetic assays are available
from Professor Nigel Richards (RichardsN14@cardiff.ac.uk) on request. Requests for
plasmids and other reagents needed to obtain the ASNS variants used in this study
should be sent to Professor Yuichiro Takagi (ytakagi@iu.edu). Raw data for the
chemoproteomic proﬁling experiments can be obtained by contacting Dr. Tyzoon
Nomanbhoy (tyzoonn@ACTIVX.com).
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